Celecoxib a Selective Cox-2 Inhibitor Mitigates Fibrosis But Not Pneumonitis Following Lung Irradiation: A Histopathological Study Publisher



Azmoonfar R^{1, 2} ; Amini P³ ; Saffar H⁴ ; Motevaseli E⁵ ; Khodamoradi E² ; Shabeeb D^{6, 7} ; Musa AE⁸ ; Najafi M² Show Affiliations
Source: Current Drug Therapy Published:2020

Abstract

Background: Lung is one of the radiosensitive and late responding organs, and is an important target for ionizing radiation. Radiation-induced pneumonitis and fibrosis are major con-sequences of lung exposure to a high dose of radiation and pose threats to the lives of exposed peo-ple. Mitigation of lung injury following an accidental radiation event or for patients with lung cancer is one of the most interesting issues in radiobiology. In the current study, we aimed to determine whether celecoxib, the most common cyclooxygenase-2 (COX-2) inhibitor, is able to mitigate pneumonitis and fibrosis following lung irradiation or not. Materials and Methods: 20 male mice were assigned to 4 groups: control, celecoxib treatment, radiation, and radiation plus celecoxib. Irradiation was performed with a dose of 18 Gy cobalt-60 (60Co) gamma rays. Celecoxib treatment (50 mg/kg) started 24 h after irradiation and continued four times per week for 4 weeks. Results: Irradiation of lung led to remarkable infiltration of macrophages, lymphocytes, mast cells and neutrophils. Also, a mild increase in fibrosis markers including accumulation of collagen, and alveolar and vascular thickening, was observed. Post-exposure treatment with celecoxib was able to mitigate fibrosis as well as alveolar and vascular changes, however, it was unable to mitigate pneu-monitis markers. Conclusion: Celecoxib showed that it may have an anti-fibrosis effect following exposure of mice lung to radiation, although it was unable to prevent pneumonitis. © 2020 Bentham Science Publishers.